XML 78 R46.htm IDEA: XBRL DOCUMENT v3.19.1
Revenues Revenues by Product (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Disaggregation of Revenue [Line Items]    
Product revenues $ 3,489.8 $ 3,131.1
TECFIDERA    
Disaggregation of Revenue [Line Items]    
Product revenues 998.8 986.9
TECFIDERA | U.S.    
Disaggregation of Revenue [Line Items]    
Product revenues 717.7 728.9
TECFIDERA | Rest of World    
Disaggregation of Revenue [Line Items]    
Product revenues 281.1 258.0
Interferon    
Disaggregation of Revenue [Line Items]    
Product revenues 500.9 550.3
Interferon | U.S.    
Disaggregation of Revenue [Line Items]    
Product revenues 327.3 371.4
Interferon | Rest of World    
Disaggregation of Revenue [Line Items]    
Product revenues 173.6 178.9
TYSABRI    
Disaggregation of Revenue [Line Items]    
Product revenues 460.4 462.1
TYSABRI | U.S.    
Disaggregation of Revenue [Line Items]    
Product revenues 245.0 249.7
TYSABRI | Rest of World    
Disaggregation of Revenue [Line Items]    
Product revenues 215.4 212.4
FAMPYRA    
Disaggregation of Revenue [Line Items]    
Product revenues 22.9 24.4
FAMPYRA | U.S.    
Disaggregation of Revenue [Line Items]    
Product revenues 0.0 0.0
FAMPYRA | Rest of World    
Disaggregation of Revenue [Line Items]    
Product revenues 22.9 24.4
ZINBRYTA    
Disaggregation of Revenue [Line Items]    
Product revenues 0.0 1.4
ZINBRYTA | U.S.    
Disaggregation of Revenue [Line Items]    
Product revenues 0.0 0.0
ZINBRYTA | Rest of World    
Disaggregation of Revenue [Line Items]    
Product revenues 0.0 1.4
MS Product Revenues    
Disaggregation of Revenue [Line Items]    
Product revenues 1,983.0 2,025.1
MS Product Revenues | U.S.    
Disaggregation of Revenue [Line Items]    
Product revenues 1,290.0 1,350.0
MS Product Revenues | Rest of World    
Disaggregation of Revenue [Line Items]    
Product revenues 693.0 675.1
SPINRAZA    
Disaggregation of Revenue [Line Items]    
Product revenues 518.5 363.9
SPINRAZA | U.S.    
Disaggregation of Revenue [Line Items]    
Product revenues 223.3 188.0
SPINRAZA | Rest of World    
Disaggregation of Revenue [Line Items]    
Product revenues 295.2 175.9
BENEPALI    
Disaggregation of Revenue [Line Items]    
Product revenues 124.0 120.9
BENEPALI | U.S.    
Disaggregation of Revenue [Line Items]    
Product revenues 0.0 0.0
BENEPALI | Rest of World    
Disaggregation of Revenue [Line Items]    
Product revenues 124.0 120.9
FLIXABI    
Disaggregation of Revenue [Line Items]    
Product revenues 14.7 6.6
FLIXABI | U.S.    
Disaggregation of Revenue [Line Items]    
Product revenues 0.0 0.0
FLIXABI | Rest of World    
Disaggregation of Revenue [Line Items]    
Product revenues 14.7 6.6
IMRALDI    
Disaggregation of Revenue [Line Items]    
Product revenues 35.7 0.0
IMRALDI | U.S.    
Disaggregation of Revenue [Line Items]    
Product revenues 0.0 0.0
IMRALDI | Rest of World    
Disaggregation of Revenue [Line Items]    
Product revenues 35.7 0.0
Biosimilars    
Disaggregation of Revenue [Line Items]    
Product revenues 174.4 127.5
Biosimilars | U.S.    
Disaggregation of Revenue [Line Items]    
Product revenues 0.0 0.0
Biosimilars | Rest of World    
Disaggregation of Revenue [Line Items]    
Product revenues 174.4 127.5
FUMADERM    
Disaggregation of Revenue [Line Items]    
Product revenues 4.1 7.0
FUMADERM | U.S.    
Disaggregation of Revenue [Line Items]    
Product revenues 0.0 0.0
FUMADERM | Rest of World    
Disaggregation of Revenue [Line Items]    
Product revenues 4.1 7.0
Product, net    
Disaggregation of Revenue [Line Items]    
Product revenues 2,680.0 2,523.5
Product, net | U.S.    
Disaggregation of Revenue [Line Items]    
Product revenues 1,513.3 1,538.0
Product, net | Rest of World    
Disaggregation of Revenue [Line Items]    
Product revenues $ 1,166.7 $ 985.5